205 related articles for article (PubMed ID: 20480739)
1. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
2. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
3. Ten years of HER2-directed therapy: still questions after all these years.
Krop IE; Winer EP
Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
[No Abstract] [Full Text] [Related]
4. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
5. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
Slamon DJ
Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
[No Abstract] [Full Text] [Related]
6. [Metastatic breast cancer--new methods of treatment].
Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H
MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641
[No Abstract] [Full Text] [Related]
7. [Targeted therapies in breast cancer].
Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
9. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Zhang B; Hurvitz S
Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
[TBL] [Abstract][Full Text] [Related]
11. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
Ritter CA; Bianco R; Dugger T; Forbes J; Qu S; Rinehart C; King W; Arteaga CL
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):642-3. PubMed ID: 15598031
[No Abstract] [Full Text] [Related]
13. HER2 as a cancer stem-cell target.
Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
[No Abstract] [Full Text] [Related]
14. New HER2-positive targeting agents in clinical practice.
Tolaney S
Curr Oncol Rep; 2014; 16(1):359. PubMed ID: 24442625
[TBL] [Abstract][Full Text] [Related]
15. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of HER2 - twice as good or twice as toxic?
Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
18. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
19. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
20. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
